Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00218335 · ClinicalTrials.gov registry record · Phase 2

A Network & Dyad HIV Prevention Intervention for IDU's - 1

A Phase 2 study, sponsored by Johns Hopkins Bloomberg School of Public Health.

Completed
Registry status
Phase 2
Development phase
1,024
Enrollment target

NCT00218335: Completed Phase 2 study, sponsored by Johns Hopkins Bloomberg School of Public Health.

NCT00218335 is a Phase 2 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 1,024 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (670% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00218335, a Phase 2 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.

COMPLETED
Registry status
Phase 2
Development phase
1,024 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate a peer-based HIV prevention intervention that targets active injection drug users and their drug and sex partners.

Interventions

  • BEHAVIORAL Control Condition
  • BEHAVIORAL Intervention Condition

Trial Details

FieldValue
Enrollment Target 1,024 participants
Start Date 2003-06
Est. Completion 2008-05
Phase Phase 2

What the finished NCT00218335 record still lists

NCT00218335 is an interventional study that assigns participants to a tested intervention. Its 1,024 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (670% higher).

The record links to 0 conditions, and to 2 interventions - of which Control Condition is the first listed.

NCT00218335 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00218335 about?

NCT00218335 is a clinical study titled "A Network & Dyad HIV Prevention Intervention for IDU's - 1". The purpose of this study is to evaluate a peer-based HIV prevention intervention that targets active injection drug users and their drug and sex partners.

What is the current status of trial NCT00218335?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,024 participants. The study started on 2003-06. Estimated completion is 2008-05.

What interventions are being tested in trial NCT00218335?

The interventions under investigation include: Control Condition (BEHAVIORAL), Intervention Condition (BEHAVIORAL).

Who is sponsoring clinical trial NCT00218335?

This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00218335's enrollment target sits among peer trials

1,024 25th of 2000 higher than 1,976 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06888011 · 1,024 participants · NA

    iAmHealthy Clinical Practice Guideline (CPG)

  • NCT02200276 · 1,025 participants · NA

    Influenza Immunization in Adults Over Age 75

  • NCT02296450 · 1,025 participants

    Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

  • NCT07216703 · 1,023 participants · Phase 3

    A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00218335, the US trial registry maintained by the National Library of Medicine. NCT00218335 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.